Johnson & Johnson (JNJ) Shares Bought by Point View Wealth Management Inc.

Point View Wealth Management Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 9,752 shares of the company’s stock after purchasing an additional 450 shares during the quarter. Point View Wealth Management Inc.’s holdings in Johnson & Johnson were worth $1,290,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. OLD Point Trust & Financial Services N A grew its holdings in shares of Johnson & Johnson by 2.2% in the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after acquiring an additional 1,321 shares during the last quarter. Lynch & Associates IN grew its holdings in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after acquiring an additional 841 shares during the last quarter. Welch & Forbes LLC grew its holdings in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after acquiring an additional 6,730 shares during the last quarter. Oakbrook Investments LLC grew its holdings in shares of Johnson & Johnson by 7.4% in the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after acquiring an additional 9,375 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after acquiring an additional 3,533 shares during the last quarter. Institutional investors own 65.90% of the company’s stock.

JNJ has been the topic of a number of recent research reports. BMO Capital Markets restated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Friday, September 1st. UBS restated a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a report on Thursday, August 31st. Cowen set a $147.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. Jefferies Group upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $157.00 in a report on Wednesday, October 11th. Finally, Citigroup lifted their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $144.59.

Johnson & Johnson (JNJ) opened at $139.37 on Monday. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $376,059.06, a price-to-earnings ratio of 19.60, a PEG ratio of 2.85 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the previous year, the company posted $1.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.41%. Johnson & Johnson’s payout ratio is 58.33%.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Point View Wealth Management Inc.” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/04/johnson-johnson-jnj-shares-bought-by-point-view-wealth-management-inc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit